Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 Jul;47(7):2800-2809.
doi: 10.1177/0300060519855869. Epub 2019 Jun 24.

A meta-analysis of MDR1 polymorphisms rs1128503 and rs1045642 and susceptibility to hepatocellular carcinoma

Qing Chang  1 , Zhong-Lin He  1 , Yu-Chong Peng  1 , Shi-Gang Duan  1 , Yu-Xin Dai  1 , Xiao-Hui Zhao  1
Affiliations
Meta-Analysis

A meta-analysis of MDR1 polymorphisms rs1128503 and rs1045642 and susceptibility to hepatocellular carcinoma

Qing Chang et al. J Int Med Res. 2019 Jul.

Abstract

Objective: A relationship between polymorphisms rs1128503 and rs1045642 in the multidrug resistance 1 gene (MDR1) and susceptibility to hepatocellular carcinoma (HCC) has been reported but is inconclusive. This study was performed to explore the significance of MDR1 polymorphisms rs1128503 and rs1045642 in screening and diagnosis of HCC.

Methods: Studies of association analyses between MDR1 gene polymorphisms rs1128503 and rs1045642 and HCC were selected from three foreign language databases (PubMed, Cochrane, and Embase) and three Chinese databases (Wanfang, China National Knowledge Infrastructure, and China Knowledge Network) and subjected to meta-analysis.

Results: We found no significant relationship between the rs1128503 polymorphism and susceptibility to HCC in 4 cohorts and no significant relationship between the rs1045642 polymorphism and susceptibility to HCC in 3 cohorts.

Conclusions: There was no relationship between polymorphisms rs1128503 or rs1045642 of the MDR1 gene and susceptibility to HCC.

Keywords: Hepatocellular carcinoma (HCC); P-glycoprotein; meta-analysis; multidrug resistance 1 (MDR1); polymorphism; susceptibility.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flow diagram of study selection process.
Figure 2.
Figure 2.
Quality assessment scale of eligible studies.
Figure 3.
Figure 3.
Forest plot of hepatocellular cancer risk associated with rs1128503 (C>T) models. (a) allele model; (b) homozygous model; (c) heterozygous model; (d) recessive model; (e) dominant model. The horizontal line indicates the lower and upper limits of the 95% CI; the square indicates the OR, with the size of the square indicating the weight of the study and the dotted red line indicating the combined OR value. The diamond represents the combined effect size, and the larger the diamond, the larger the confidence interval. A cross between the diamond and the ineffective line indicates no statistical correlation between the factors studied and the outcome; if the diamond falls on the left side of the invalid vertical line, it indicates a protective factor; if the diamond falls on the right side of the line, it indicates a risk factor. OR, odds ratio; CI, confidence interval.
Figure 4.
Figure 4.
Forest plot of hepatocellular cancer risk associated with rs1045642 (C>T) models. (a) allele model; (b) homozygous model; (c) heterozygous model; (d) recessive model; (e) dominant model. The horizontal line indicates the lower and upper limits of the 95% CI; the square indicates the OR, with the size of the square indicating the weight of the study and the dotted red line indicating the combined OR value. The diamond represents the combined effect size, and the larger the diamond, the larger the confidence interval. A cross between the diamond and the ineffective line indicates no statistical correlation between the factors studied and the outcome; if the diamond falls on the left side of the invalid vertical line, it indicates a protective factor; if the diamond falls on the right side of the line, it indicates a risk factor. OR, odds ratio; CI, confidence interval.
See this image and copyright information in PMC

References

    1. Wang JB, Abnet CC, Chen W, et al. Association between serum 25(OH) vitamin D, incident liver cancer and chronic liver disease mortality in the Linxian Nutrition Intervention Trials: a nested case-control study. Br J Cancer 2013; 109: 1997–2004. - PMC - PubMed
    1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87–108. - PubMed
    1. McGlynn KA, Petrick JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis 2015; 19: 223–238. - PMC - PubMed
    1. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547–553. - PubMed
    1. Jamroziak K, Mlynarski W, Balcerczak E, et al. Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol 2004; 72: 314–321. - PubMed

MeSH terms

Substances